Art. -Nr.: HY-19824

3PO

31 Cited Publications

Kundenbewertung

Based on 31 publication(s) in Google Scholar

3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC₅₀s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD⁺ and NADH. 3PO can be used for the research of cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 18550-98-6
Formel: C₁₃H₁₀N₂O
Molecular Weight:210.23

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

3PO Chemical Structure

CAS. Nr.: 18550-98-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (31)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Epithelial cell	IC₅₀	1.4 μM Compound: 1; 3PO	Cytotoxicity against human Epithelial cell assessed as cell growth inhibition Cytotoxicity against human Epithelial cell assessed as cell growth inhibition	[PMID: 32679452]

In Vitro

3PO (0-33 μM; 0-36 h) inhibits Jurkat cells proliferation by influence cell cycle^[1].
3PO (10 μM/L; 0-36 h) suppresses glycolytic flux to lactate in Jurkat cells^[1].
3PO (10 μM/L; 0-36 h) inhibits cellular proliferation of transformed tumor cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Jurkat cells
Concentration:

0.3, 1, 3, 10 and 33 μM
Incubation Time:

0, 4, 8, 16, 24 and 36 hours
Result:

Inhibited Jurkat T cells proliferation by G2-M phase cell cycle arrest.

Cell Viability Assay^[1]

Cell Line:

Jurkat cells
Concentration:

0.3, 1, 3, 10 and 33 μM
Incubation Time:

0, 4, 8, 16, 24 and 36 hours
Result:

Decreased lactate secretion, NADH, NAD⁺ and ATP in Jurkat cells.

Cell Proliferation Assay^[1]

Cell Line:

Jurkat, K562, HL-60, MDA-MB231, HL-60, HeLa, Melanoma and Lewis Lung
Concentration:

0-20 μM
Incubation Time:

0, 4, 8, 16, 24 and 36 hours
Result:

Inhibited solid tumor and hematologic cell lines with IC₅₀s of 1.4-24 μM/L.

In Vivo

3PO (0.07 mg/g; i.p. once per day for 14 days) inhibits the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice^[1].
3PO (0.07 mg/g; i.p. three sequential daily injections followed by 3 off days for 14 days) inhibits the tumor growth in BALB/c athymic mice^[1].
3PO (0.07 mg/g; i.p. two daily injections followed a 7-day rest for 14 days) inhibits the tumor growth in BALB/c athymic mice^[1].
3PO (0.07 mg/g; i.p. once) inhibits Fru-2,6-BP and glucose uptake in C57Bl/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57Bl/6 mice with Lewis lung carcinoma xenografts^[1]
Dosage:

0.07 mg/g
Administration:

Intraperitoneal injection; 0.07 mg/g once a day; for 14 days
Result:

Suppressed the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice compared to the control group.

Animal Model:

Female BALB/c athymic mice with MDA-MB231 human breast adenocarcinoma xenografts^[1]
Dosage:

0.07 mg/g
Administration:

Intraperitoneal injection; 0.07 mg/g three sequential daily injections of either DMSO or 3PO followed by 3 off days; for 14 days
Result:

Suppressed xenograft tumorigenic growth of MDA-MB231 cells compared with the controls.

Animal Model:

Female BALB/c athymic mice with HL-60 leukemia xenografts^[1]
Dosage:

0.07 mg/g
Administration:

Intraperitoneal injection; 0.07 mg/g two daily injections followed a 7-day rest; for 14 days
Result:

Suppressed xenograft tumorigenic growth of HL-60 leukemia compared with the controls, especially from the second administration cycle.

Animal Model:

Female C57Bl/6 mice with Lewis lung carcinoma xenografts^[1]
Dosage:

0.07 mg/g
Administration:

Intraperitoneal injection; once
Result:

Decreased Fru-2,6-BP and glucose uptake in C57Bl/6 mice compared to control group.

Chemical Information

CAS. Nr. 18550-98-6
Appearance Solid
Molecular Weight 210.23
Formel C₁₃H₁₀N₂O
Color Light yellow to yellow
SMILES

O=C(C1=CC=NC=C1)/C=C/C2=CC=CN=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (31)

All ELISACell Autophagy AssayIHCFlow Cytometry

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. [Abstract]

2022 Sep 1;7(1):303. PMID: 36045132
Nat Metab

HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma. [Abstract]

2022 Oct;4(10):1306-1321. PMID: 36192599
Adv Sci (Weinh)

Fatty Acid Oxidation-Glycolysis Metabolic Transition Affects ECM Homeostasis in Silica-Induced Pulmonary Fibrosis. [Abstract]

2024 Dec 25:e2407134. PMID: 39721015
Redox Biol

Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis. [Abstract]

2021 Oct:46:102082. PMID: 34343908
Acta Pharmacol Sin

SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. [Abstract]

2024 Dec;45(12):2579-2597. PMID: 39294445

3PO purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Dec;45(12):2579-2597. [Abstract]

BMDMs isolated from C57BL/6J mice were incubated for 12 h with 10 μmol/L 3PO or vehicle in the presence of LPS (100 ng/mL) + IFN-γ (50 ng/mL). The supernatant levels of pro-inflammatory and anti-inflammatory cytokines measured by ELISA. n = 6 per group. The results showed that 3PO significantly reduced the supernatant levels of TNF-α and IL-6.

3PO purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Dec;45(12):2579-2597. [Abstract]

BMDMs isolated from C57BL/6J mice were incubated for 12 h with 10 μmol/L 3PO or vehicle in the presence of LPS (100 ng/mL) + IFN-γ (50 ng/mL). The MFI of CD80 and CD86, and CD206 detected by flow cytometry. n = 3 per group. n = 6 per group. The results showed that 3PO significantly reduced the MFI of CD86, whereas it markedly increased the MFI of CD206.
J Transl Med

Vitamin D attenuates the progression of pulmonary fibrosis via inhibiting thymidine kinase 1/PFKFB3-driven glycolysis. [Abstract]

2026 Apr 22;24(1):571. PMID: 42021376
Blood Adv

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. [Abstract]

2024 May 14;8(9):2312-2325. PMID: 38295283
Arch Toxicol

CuO-NPs-triggered heterophil extracellular traps exacerbate liver injury in chicks by promoting oxidative stress and inflammatory responses. [Abstract]

2022 Nov;96(11):2913-2926. PMID: 35962800

3PO purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2022 Nov;96(11):2913-2926. [Abstract]

Cells were intervened with specific inhibitors Ritonavir, 3PO (24 μM), STF-31, NSC23766, AZD3965, and 3-bromopyruvic acid for 30 min, and then incubated for 2 h with CuO-NPs (20 μg/mL). The results showed that 3PO significantly inhibited the release of HETs.
J Agric Food Chem

Glycolysis and Reactive Oxygen Species Production Participate in T-2 Toxin-Stimulated Chicken Heterophil Extracellular Traps. [Abstract]

2021 Nov 3;69(43):12862-12869. PMID: 34694797

3PO purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2021 Nov 3;69(43):12862-12869. [Abstract]

T-2-triggered HET formation is dependent on PFKFB3, lactate transport, and hexokinase II. Heterophils were stimulated with T-2 (80 ng/mL) for 90 min in the inhibitors 3PO (24 μM), AZD3965, and 3-Bromopyruvic (n = 5). Zymosan (1 mg/mL) was the positive control. The results showed that 3PO significantly inhibited HET formation.
Ecotoxicol Environ Saf

Paracrine signaling of ferroptotic airway epithelium in crystalline silica-induced pulmonary fibrosis augments local fibroblast activation through glycolysis reprogramming. [Abstract]

2024 Feb:271:115994. PMID: 38262094
Cancer Cell Int

RORα inhibits gastric cancer proliferation through attenuating G6PD and PFKFB3 induced glycolytic activity. [Abstract]

2024 Jan 6;24(1):12. PMID: 38184549

3PO purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jan 6;24(1):12. [Abstract]

RORα deletion promotes GC proliferation induced by 3PO and DHEA in vivo The expression levels of Ki-67 and PCNA were detected through immunohistochemistry stain and MOD method in subcutaneous tumor of mice. Original 200 and 400 magnification. Scale bar = 100 μm. N = 3. The RORα-KO-MFC cells treated with 3PO (25 µM; 48 h) or DHEA (250 µM) were injected into subcutaneous flank of mice until the tumor volume reached 100 to 300 mm³.
Cell Prolif

Cathepsin K deficiency promotes alveolar bone regeneration by promoting jaw bone marrow mesenchymal stem cells proliferation and differentiation via glycolysis pathway. [Abstract]

2021 Jul;54(7):e13058. PMID: 34053135
Pharmaceuticals (Basel)

Investigating the Role of Glycolysis in Xuefu Zhuyu Capsule-Promoted Angiogenesis in Endothelial Cells: A Study Based on Network Pharmacology, Molecular Docking, and In Vitro Validation. [Abstract]

2025 Dec 17;18(12):1902. PMID: 41471391
Biomolecules

PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway. [Abstract]

2023 Jul 3;13(7):1072. PMID: 37509108
Int Immunopharmacol

Albiflorin contributes to Xuebijing-mediated protection against sepsis-associated acute kidney injury by modulating the succinate-PFKFB3 immunometabolic axis. [Abstract]

2026 May 14:182:116841. PMID: 42134292
Am J Physiol Cell Physiol

Inflammation-induced PFKFB3-mediated glycolysis promoting myometrium contraction through the PI3K-Akt-mTOR pathway in preterm birth mice. [Abstract]

2025 Feb 5. PMID: 39907705
mSystems

Inhibition of PFKFB3 in macrophages ameliorates intestinal inflammation by modulating gut microbiota in DSS-induced colitis. [Abstract]

2025 Dec 11:e0063225. PMID: 41378888
Poult Sci

Gliotoxin elicits immunotoxicity in the early innate immune system of ducks. [Abstract]

2024 Jun;103(6):103717. PMID: 38643746
Virol Sin

Thapsigargin suppresses porcine hemagglutinating encephalomyelitis virus replication by disrupting host energy metabolism. [Abstract]

2025 Nov 21:S1995-820X(25)00161-0. PMID: 41276220
Fish Shellfish Immunol

Zinc oxide nanoparticles (ZnO-NPs) exhibit immune toxicity to crucian carp (Carassius carassius) by neutrophil extracellular traps (NETs) release and oxidative stress. [Abstract]

2022 Oct:129:22-29. PMID: 35932984
ACS Chem Neurosci

Cdh1-Mediated Metabolic Switch from Pentose Phosphate Pathway to Glycolysis Contributes to Sevoflurane-Induced Neuronal Apoptosis in Developing Brain. [Abstract]

2019 May 15;10(5):2332-2344. PMID: 30741526
Vet Res

Neospora caninum hijacks host PFKFB3-driven glycolysis to facilitate intracellular propagation of parasites. [Abstract]

2025 Apr 30;56(1):94. PMID: 40307939
Food Chem Toxicol

Diacetoxyscirpenol-induced heterophil extracellular traps contribute to the immune toxicity of liver injury in chickens. [Abstract]

2021 Feb:148:111926. PMID: 33352262
Toxicol Appl Pharmacol

PFKFB3 promotes endotoxemia-induced myocardial dysfunction through inflammatory signaling and apoptotic induction. [Abstract]

2019 Apr 1:368:26-36. PMID: 30776389
J Inorg Biochem

Nanosilver-stimulated heterophil extracellular traps promoted liver and kidney injury in chicken. [Abstract]

2022 Apr 20;233:111838. PMID: 35504082
Front Biosci (Landmark Ed)

Inhibition of PFKFB3 Expression Stimulates Macrophage-Mediated Lymphangiogenesis Post-Acute Myocardial Infarction. [Abstract]

2023 Nov 3;28(11):277. PMID: 38062830
Vet Parasitol

Neospora caninum triggers the release of heterophil extracellular traps in chickens. [Abstract]

2025 Apr 15:337:110471. PMID: 40245810
Res Sq

2024 Nov 11.
SSRN

6 Oct 2022.
Research Square Print

2022 May.
Research Square Preprint

2022.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 60 mg/mL (285.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7567 mL

23.7835 mL

47.5670 mL

5 mM

0.9513 mL

4.7567 mL

9.5134 mL

10 mM

0.4757 mL

2.3783 mL

4.7567 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Clem B, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008 Jan;7(1):110-20. [Content Brief]

[2]. Schoors S, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 Jan 7;19(1):37-48. [Content Brief]

[3]. Lea MA, Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. Anticancer Res. 2015 Nov;35(11):5889-99. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.7567 mL	23.7835 mL	47.5670 mL	118.9174 mL
	5 mM	0.9513 mL	4.7567 mL	9.5134 mL	23.7835 mL
	10 mM	0.4757 mL	2.3783 mL	4.7567 mL	11.8917 mL
	15 mM	0.3171 mL	1.5856 mL	3.1711 mL	7.9278 mL
	20 mM	0.2378 mL	1.1892 mL	2.3783 mL	5.9459 mL
	25 mM	0.1903 mL	0.9513 mL	1.9027 mL	4.7567 mL
	30 mM	0.1586 mL	0.7928 mL	1.5856 mL	3.9639 mL
	40 mM	0.1189 mL	0.5946 mL	1.1892 mL	2.9729 mL
	50 mM	0.0951 mL	0.4757 mL	0.9513 mL	2.3783 mL
	60 mM	0.0793 mL	0.3964 mL	0.7928 mL	1.9820 mL
	80 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4865 mL
	100 mM	0.0476 mL	0.2378 mL	0.4757 mL	1.1892 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

3PO

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 3PO

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

3PO

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 3PO

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

3PO Related Classifications

HY-19824 Related Classifications